European Nanomedicine Characterization Laboratory — EUNCL

Texte zu diesem Projekt


Erfasste Texte

In order to accelerate the development of the nanomedicine business in Europe, EU-NCL interconnects 8 European and 1 American key reference facilities with a proven expertise in physical, chemical, in vitro and in vivo biological characterisation of nanoparticles for medical applications. The objective is to reach a level of international excellence in nanomedicine characterization for all medical indication, and make it accessible to all organisations developing candidate nanomedicines prior to their submission to the regulatory agencies in order to get the approval for clinical trials and later the marketing authorization. EU-NCL is partnered with the sole international reference facility namely the Nanotechnology Characterisation Lab of the USA to get a faster international harmonization of analytical protocols. EU-NCL is closely connected to national medicine agencies and to the European Medicine Agency in order to permanently adapt its analytical services to the need and requests of the regulators. EU-NCL is designed, organized and operated according to the highest EU regulatory and quality standards in order to provide a full analytical cascade of 42 assays. Within EU-NCL, 6 analytical facilities will offer a Trans National Access to their existing analytical services but they will also develop new or improved analytical assays under the Joint Research Activities in order to keep EU-NCL at the cutting edge of the nanomedicine characterisation. A complementary set of networking activities will make EU-NCL able to deliver to the European academic or industrial scientists the best analytical services they dramatically require for accelerating the industrial development of their candidate nanomedicines. An exploitation and business plan will be proposed at the end of the project in order to submit a sustainable development plan beyond the initial period of 4 years.